show reduced binding to heparan sulfate, heightened viremia, and slower
clearance from the circulation. J. Virol. 74:644–651.
Cardin, A. D., and H. J. R. Weintraub. 1989. Molecular modeling of proteinglycosoaminoglycan interactions. Arteriosclerosis 9:21–32.
Denizot, F., and R. Lang. 1986. Rapid colorimetric assay for cell growth and
survival. Modifications to the tetrazolium dye procedure giving improved
sensitivity and reliability. J. Immunol. Methods 89:271–277.
Feyzi, E., E. Trybala, T. Bergstrom, U. Lindahl, and D. Spillman. 1997.
Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J. Biol. Chem. 272:
24850–24857.
Fotiadis, C., D. R. Kilpatrick, and H. L. Lipton. 1991. Comparison of the
binding characteristics to BHK-21 cells of viruses representing the two Theiler's virus neurovirulence groups. Virology 182:365–370.
Friedmann, A., and H. L. Lipton. 1980. Replication of GDVII and DA
strains of Theiler's murine encephalomyelitis virus in BHK 21 cells: an
electron microscopic study. Virology 101:389–398.
Fry, E. E., S. M. Lea, T. Jackson, J. W. Newman, F. M. Ellard, W. E.
Blakemore, R. Abu Ghazaleh, A. Samuel, A. M. Q. King, and D. I. Stuart.
1999. The structure and function of a foot-and-mouth disease-virus oligosaccharide receptor complex. EMBO J. 18:543–554.
Goto, A., D. Hayasaka, K. Yoshii, T. Mizutani, H. Kariwa, and I. Takashima.
2003. A BHK-21 cell culture-adapted tick-borne encephalitis virus mutant is
attenuated for neuroinvasiveness. Vaccine 21:4043–4051.
Guido, D., X. M. Bai, B. Van Der Schueren, J.-J. Cassiman, and H. Van Den
Berghe. 1992. Developmental changes in heparan sulfate expression: in situ
detection with mAbs. J. Cell Biol. 119:961–975.
Hartmann, U., and P. Maurer. 2001. Proteoglycans in the nervous system—
the quest for functional roles in vivo. Matrix Biol. 20:23–35.
Heil, M. L., A. Albee, J. H. Strauss, and R. J. Kuhn. 2001. An amino acid
substitution in the coding region of the E2 glycoprotein adapts Ross River
virus to utilize heparan sulfate as an attachment moiety. J. Virol. 75:6303–
6309.
Herold, B. C., S. I. Gerber, B. J. Belval, A. M. Siston, and N. Shulman. 1996.
Differences in the susceptibility of herpes simplex virus types 1 and 2 to
modified heparin compounds suggest serotype differences in viral entry.
J. Virol. 70:3461–3469.
Hileman, R. E., J. R. Fromm, J. M. Weiler, and R. J. Linhardt. 1998.
Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 20:156–167.
Hulst, M. M., H. G. van Gennip, A. C. Vlot, E. Schooten, A. J. de Smit, and
R. J. Moormann. 2001. Interaction of classical swine fever virus with membrane-associated heparan sulfate: role for virus replication in vivo and vir-3. ulence. J. Virol. 75:9585–9595.
